Dr. Marina D’Angelo, CSO, discussed development of ECPF-1, the novel, injectable therapeutic that slows the progression of osteoarthritis.
ProteaPex Therapeutics is presenting several posters at the 2018 Experimental Biology meeting in San Diego, CA. In addition, we are featured in a short film as part of the Thought Leadership Series.
Our periodontal disease therapeutic, ECPF-2, is the subject of a proof-of-concept competition grant proposal to the University City Science Center. The winners will be announced early 2017.
Marina D'Angelo, PhD, CSO and co-founder of ProteaPex Therapeutics, was the recent subject of a Faculty Spotlight.
Our lead OA product, ECPF-1, was recently featured on public radio in a segment on pet osteoarthritis.